Valuation: AbbVie Inc.

Market Cap 450B 394B 363B 337B 640B 42,935B 649B 4,346B 1,691B 21,075B 1,690B 1,653B 73,070B P/E 2026 *
31.1x
P/E 2027 * 23.9x
Enterprise Value 506B 443B 408B 379B 719B 48,258B 729B 4,885B 1,901B 23,688B 1,900B 1,858B 82,130B EV / Sales 2026 *
7.52x
EV / Sales 2027 * 6.83x
Free-Float
95.71%
Yield 2026 *
2.69%
Yield 2027 * 2.84%
1 day+1.08%
1 week+2.37%
Current month+2.37%
1 month+15.48%
3 months+24.83%
6 months+10.36%
Current year+12.74%
1 week 247.56
Extreme 247.56
261.64
1 month 215.37
Extreme 215.37
261.64
Current year 190.75
Extreme 190.75
261.64
1 year 184.63
Extreme 184.63
261.64
3 years 132.7
Extreme 132.7
261.64
5 years 105.56
Extreme 105.56
261.64
10 years 55.06
Extreme 55.0623
261.64
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Director

62 0.0000%
06-29Free

Director

134 0.0000%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+2.37%+37.29%+90.11% 450B
+3.07%+3.14%+60.07%+173.66% 1,070B
+3.46%+5.84%+73.11%+68.78% 624B
+2.15%-2.07%+27.62%+22.57% 328B
+2.11%+2.06%+40.83%+42.33% 292B
+1.30%+0.21%+29.95%+49.38% 284B
+1.98%+4.29%-25.63%-38.90% 217B
+0.98%+2.32%+26.48%+69.45% 198B
+4.04%+7.16%+21.12%+81.93% 161B
+1.71%+0.44%-4.18%-31.93% 135B
Average +2.15%+0.62%+28.67%+52.74% 375.95B
Weighted average by Cap. +2.37%+0.58%+42.21%+84.39%

Financials

2026 *2027 *
Net sales 67.24B 58.89B 54.24B 50.34B 95.6B 6,414B 96.9B 649B 253B 3,148B 253B 247B 10,915B 72.73B 63.7B 58.67B 54.46B 103B 6,938B 105B 702B 273B 3,406B 273B 267B 11,808B
Net income 14.56B 12.75B 11.75B 10.9B 20.7B 1,389B 20.98B 141B 54.72B 682B 54.68B 53.48B 2,364B 19.02B 16.66B 15.35B 14.24B 27.05B 1,815B 27.41B 184B 71.49B 891B 71.44B 69.87B 3,088B
Net Debt 55.81B 48.88B 45.02B 41.79B 79.35B 5,324B 80.43B 539B 210B 2,613B 210B 205B 9,060B 46.34B 40.58B 37.38B 34.69B 65.88B 4,420B 66.77B 447B 174B 2,170B 174B 170B 7,522B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-07 US$257.61 +1.12% 1,258,131
26-07-06 US$254.76 -2.42% 8,580,220
26-07-02 US$261.07 +3.99% 7,114,422
26-07-01 US$251.06 -0.23% 6,987,982
26-06-30 US$251.64 -1.05% 6,999,707
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
254.76USD
Average target price
258.32USD
Spread / Average Target
+1.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock